Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Stock Information for Sigyn Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sigyn Therapeutics Inc.

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA(TM) (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
Tonix Pharmaceuticals Presented Data on Tonmya(TM) (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.